TerrAscend TSNDF
OTC TSNDF
$0.63 +0.02 (+3.54%)
As of: Aug 21, 2026 · 3:59 PM EDT

TerrAscend (TSNDF) Net Income towards Common Stockholders (2021 - 2026)

TerrAscend (TSNDF) posted quarterly Net Income towards Common Stockholders of -$1.2 million for Q1 2026, up 74.48% year-over-year from -$673434.6 in Q1 2025, and down 128.59% quarter-over-quarter from $4.1 million in Q4 2025.

TerrAscend (TSNDF) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends

TerrAscend (TSNDF) has reported Net Income towards Common Stockholders for 6 consecutive years, with -$1.2 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Net Income towards Common Stockholders rose 74.48% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at -$53.4 million (down 5.3% YoY), while the FY2025 annual figure was -$56.8 million, down 9.78% from the prior year.
  • Net Income towards Common Stockholders fell to -$1.2 million in Q1 2026 per TSNDF's latest filing, from $4.1 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $4.1 million in Q4 2025 and bottomed at -$54.7 million in Q4 2023.
  • Historically, Net Income towards Common Stockholders has averaged -$12.0 million across 5 years, with a median of -$4.6 million in 2025.
  • On a YoY basis, Net Income towards Common Stockholders climbed as much as 110.13% in 2025 and fell as far as 86977.08% in 2025.
  • TerrAscend's Net Income towards Common Stockholders stood at -$10.6 million in 2022, then plunged by 417.02% to -$54.7 million in 2023, then gained by 25.74% to -$40.6 million in 2024, then jumped by 110.13% to $4.1 million in 2025, then plunged by 128.59% to -$1.2 million in 2026.
  • Business Quant data shows TSNDF's Net Income towards Common Stockholders at -$1.2 million in Q1 2026, $4.1 million in Q4 2025, and -$14.6 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 44.51 Bn 43.55 Bn - -
2 Teva Pharmaceutical Industries 43.52 Bn 39.86 Bn 2.15 Bn -576.00 Mn
3 Zoetis 32.43 Bn 30.75 Bn 1.05 Bn 866.00 Mn
4 Takeda Pharmaceutical 28.63 Bn 22.83 Bn 5.10 Bn 710.19 Mn
5 United Therapeutics 21.87 Bn 19.21 Bn 683.80 Mn 333.00 Mn
6 Viatris 18.98 Bn 18.09 Bn 1.46 Bn -118.80 Mn
7 Neurocrine Biosciences 15.43 Bn 15.04 Bn 935.80 Mn 144.40 Mn
8 Elanco Animal Health 12.02 Bn 11.49 Bn 798.00 Mn 54.00 Mn
9 Dr Reddys Laboratories 10.14 Bn 9.98 Bn - -
10 TerrAscend 197.99 Mn 155.88 Mn 36.25 Mn -8.06 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 2.00 Mn
Mar 31, 2026 -1.18 Mn
Dec 31, 2025 4.11 Mn
Sep 30, 2025 -14.65 Mn
Jun 30, 2025 -41.70 Mn
Mar 31, 2025 -4.60 Mn
Dec 31, 2024 -40.59 Mn
Sep 30, 2024 -5.58 Mn
Jun 30, 2024 48,000.00
Mar 31, 2024 -14.85 Mn
Dec 31, 2023 -54.66 Mn
Sep 30, 2023 -232,000.00
Jun 30, 2023 -621,000.00
Mar 31, 2023 -3.59 Mn
Dec 31, 2022 -10.57 Mn
Sep 30, 2022 -10.42 Mn
Jun 30, 2022 -2.70 Mn
Mar 31, 2022 -2.26 Mn
Dec 31, 2021 2.35 Mn
Sep 30, 2021 55.84 Mn